Nektar Therapeutics (BMV:NKTR)

Nektar Therapeutics Ratios and Metrics

Market cap in millions MXN. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 27, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	19,166	3,213	2,012	7,924	46,593	56,929
Market Cap Growth	357.77%	59.68%	-74.61%	-82.99%	-18.16%	-19.66%
Enterprise Value	19,182	4.48	-1,802	632.18	35,283	39,719
PE Ratio	-	-1.60	-0.39	-1.15	-4.72	-6.83
PS Ratio	13.56	1.76	1.20	4.63	24.59	20.02
PB Ratio	-41.98	2.84	0.83	1.16	3.69	2.84
P/TBV Ratio	-314.46	3.15	0.82	1.15	3.64	2.82
P/FCF Ratio	-	-0.98	-0.56	-1.38	-5.86	-9.55
P/OCF Ratio	-	-0.98	-0.56	-1.40	-6.07	-9.77
EV/Sales Ratio	13.80	0.00	-1.08	0.37	18.62	13.97
EV/EBITDA Ratio	-	0.00	0.38	-0.09	-4.39	-5.20
EV/EBIT Ratio	-	0.00	0.37	-0.09	-4.25	-5.02
EV/FCF Ratio	-5.47	0.00	0.50	-0.11	-4.44	-6.66
Debt / Equity Ratio	-3.06	1.36	0.75	0.31	0.19	0.13
Debt / EBITDA Ratio	-0.69	-0.56	-0.46	-0.36	-0.33	-0.37
Debt / FCF Ratio	-0.52	-0.58	-0.61	-0.42	-0.33	-0.47
Asset Turnover	0.29	0.28	0.16	0.10	0.08	0.09
Inventory Turnover	-	3.81	1.91	1.24	1.60	1.39
Quick Ratio	2.46	4.16	5.95	7.49	8.88	9.51
Current Ratio	2.61	4.26	6.45	8.00	9.34	9.83
Return on Equity (ROE)	-853.17%	-208.36%	-110.95%	-70.39%	-59.64%	-35.80%
Return on Assets (ROA)	-55.07%	-52.93%	-47.53%	-41.52%	-33.63%	-24.21%
Return on Capital (ROIC)	-267.17%	-249.31%	-195.26%	-145.30%	-118.50%	-68.56%
Return on Capital Employed (ROCE)	-74.57%	-63.13%	-53.31%	-44.93%	-36.34%	-27.91%
Earnings Yield	-12.03%	-62.37%	-256.49%	-87.17%	-21.17%	-14.65%
FCF Yield	-18.31%	-102.55%	-178.82%	-72.67%	-17.07%	-10.47%
Buyback Yield / Dilution	-0.10%	-15.70%	-0.03%	-0.18%	-1.33%	-0.76%
Total Shareholder Return	-	-15.70%	-0.03%	-0.18%	-1.33%	-0.76%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.